Viatris Inc.
corporate_fare Company Profile
Viatris Inc. (NASDAQ:VTRS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for VTRS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-08, rated 9/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for VTRS spans SC TO-C, 8-K, FWP, 424B5.
Recent high-impact activity:
- Viatris Launches $1.65B Tender Offer for Pacira at $36.50/Share; $62M Break Fee Disclosed
- Viatris to Acquire Pacira BioSciences for $1.65B in Cash, Adding Non-Opioid Pain Franchise
- Viatris Sells Tyrvaya for Up to $100M, Lifts 2026 Guidance
- Viatris Reports Strong Q2, Raises Full-Year Guidance, and Announces Key Product Approvals
- Viatris Beats Q2 Estimates, Lifts 2026 Profit Outlook on Branded Drug Strength
Financial Snapshot
Short Interest & Short Volume
5.57 days to coverFINRA reported short interest of 40,790,228 shares in VTRS as of the September 15, 2026 settlement, a 5.6% increase from the prior period — about 5.6 days to cover at its recent average daily volume. On October 8, 2026, 51.0% of VTRS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for VTRS, detected from its recent SEC filings · based on capital-structure filings through 2026-06-15.
Senior Notes Priced · Refinancing Strategy
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →